Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3469-3475

  Govindarajan, Baskaran ^a   Mizesko, Melissa C ^b   Miller, Mark Steven ^b   Onda, Hiroaki ^c   Nunnelly, Matthew ^a   Casper, Katherine ^a   Brat, Daniel ^a   Cohen, Cynthia ^a   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; MITOGEN ACTIVATED PROTEIN KINASE; TUBERIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME INACTIVATION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HETEROZYGOSITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

ANGIOGENIC PROTEINS; ANIMALS; CELL LINE, TUMOR; DNA; ENZYME INHIBITORS; EXONS; GENE DELETION; GENES, DOMINANT; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0041333070     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den, O. A., Halley, D., Young, J., Burley, M., Jeremiah, S., Woodward, K., Nahmias, J., Fox, M., Ekong, R., Osborne, J., Wolfe, J., Povey, S., Snell, R. G., Cheadle, J. P., Jones, A. C., Tachataki, M., Ravine, D., and Kwiatkowski, D. J. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (Wash. DC), 277: 805-808, 1997.
2. Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell, 75: 1305-1315, 1993.
3. Plank, T. L., Yeung, R. S., and Henske, E. P. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res., 58: 4766-4770, 1998.
4. Wienecke, R., Maize, J. C., Jr., Shoarinejad, F., Vass, W. C., Reed, J., Bonifacino, J. S., Resau, J. H., de Gunzburg, J., Yeung, R. S., and DeClue, J. E. Co-localization of the TSC2 product tuberin with its target Rapl in the Golgi apparatus. Oncogene, 13: 913-923, 1996.
5. Xiao, G. H., Shoarinejad, F., Jin, F., Golemis, E. A., and Yeung, R. S. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J. Biol. Chem., 272: 6097-6100, 1997.
6. Knudson, A. G., Jr. Hereditary cancer. JAMA, 241: 279, 1979.
7. Bajenaru, M. L., Donahoe, J., Corral, T., Reilly, K. M., Brophy, S., Pellicer, A., and Gutmann, D. H. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia, 33: 314-323, 2001.
8. Henske, E. P., Scheithauer, B. W., Short, M. P., Wollmann, R., Nahmias, J., Hornigold, N., van Slegtenhorst, M., Welsh, C. T., and Kwiatkowski, D. J. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am. J. Hum. Genet., 59: 400-406, 1996.
9. Pasumarthi, K. B., Nakajima, H., Nakajima, H. O., Jing, S., and Field, L., J. Enhanced cardiomyocyte DNA synthesis during myocardial hypertrophy in mice expressing a modified TSC2 transgene. Circ. Res., 86: 1069-1077, 2000.
10. DeClue, J. E., Heffelfinger, S., Benvenuto, G., Ling, B., Li, S., Rui, W., Vass, W. C., Viskochil, D., and Ratner, N. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J. Clin. Investig., 105: 1233-1241, 2000.
11. de Paulsen, N., Brychzy, A., Fournier, M. C., Klausner, R. D., Gnarra, J. R., Pause, A., and Lee, S. Role of transforming growth factor-α in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl. Acad. Sci. USA, 98: 1387-1392, 2001.
12. Nielsen, G. P., Stemmer-Rachamimov, A. O., Ino, Y., Moller, M. B., Rosenberg, A. E., and Louis, D. N. Malignant transformation of neurofibromas in neurofibromatosis I is associated with CDKN2A/p16 inactivation. Am. J. Pathol., 155: 1879-1884, 1999.
13. Grady, B., Goharderakhshan, R., Chang, J., Ribeiro-Filho, L. A., Perinchery, G., Franks, J., Presti, J., Carroll, P., and Dahiya, R. Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma. J. Urol., 166: 1088-1092, 2001.
14. Onda, H., Lueck, A., Marks, P. W., Warren, H. B., and Kwiatkowski D. J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background J. Clin. Investig., 104: 687-695, 1999.
15. Arbiser, J. L., Weiss, S. W., Arbiser, Z. K., Bravo, F., Govindajaran, B., Caceres-Rios, H., Cotsonis, G., Recavarren, S., Swerlick, R. A., and Cohen, C. Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: Implications for biologic behavior and response to therapy. J. Am. Acad. Dermatol., 44: 1-5, 2001.
16. Arbiser, J. L., Brat, D., Hunter, S., D'Armiento, J., Henske, E. P., Arbiser, Z. K., Bai, X., Goldberg, G., Cohen, C., and Weiss, S. W. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J. Am. Acad. Dermatol., 46: 376-380, 2002.
17. Arbiser, J. L., Raab, G., Rohan, R. M., Paul, S., Hirschi, K., Flynn, E., Price, E. R., Fisher, D. E., Cohen, C., and Klagsbrun, M. Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am. J. Pathol., 155: 723-729, 1999.
18. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell, 77: 841-852, 1994.
19. Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H. R., and Folkman, J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA, 94: 861-866, 1997.
20. Gressani, K. M., Rollins, L. A., Leone-Kabler, S., Cline, J. M., and Miller, M. S. Induction of mutations in Ki-ras and INK4a in liver tumors of mice exposed in utero to 3-methylcholanthrene. Carcinogenesis (Lond.), 19: 1045-1052, 1998.
21. Gressani, K. M., Leone-Kabler, S., O'Sullivan, M. G., Case, L. D., Malkinson, A. M., and Miller, M. S. Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. Carcinogenesis (Lond.), 20: 2159-2165, 1999.
22. Rollins, L. A., Leone-Kabler, S., O'Sullivan, M. G., and Miller, M. S. Role of tumor suppressor genes in transplacental lung carcinogenesis. Mol. Carcinog., 21: 177-184, 1998.
23. Zakut-Houri, R., Oren, M., Bienz, B., Lavie, V., Hazum, S., and Givol, D. A single gene and a pseudogene for the cellular tumour antigen p53. Nature (Lond.), 306: 594-597, 1983.
24. Hegi, M. E., Soderkvist, P., Foley, J. F., Schoonhoven, R., Swenberg, J. A., Kari, F., Maronpot, R., Anderson, M. W., and Wiseman, R. W. Characterization of p53 mutations in methylene chloride- induced lung tumors from B6C3F1 mice. Carcinogenesis (Lond.), 14: 803-810, 1993.
25. Arbiser, J. L., Yeung, R., Weiss, S. W., Arbiser, Z. K., Amin, M. B., Cohen, C., Frank, D., Mahajan, S., Herron, G. S., Yang, J., Onda, H., Zhang, H. B., Bai, X., Uhlmann, E., Loehr, A., Northrup, H., Au, P., Davis, I., Fisher, D. E., and Gutmann, D. H. The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am. J. Pathol., 159: 483-491, 2001.
26. Arbiser, J. L., Govindarajan, B., Bai, X., Onda, H., Kazlauskas, A., Lim, S. D., Amin, M. B., and Claesson-Welsh, L. Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-β in tuberous sclerosis. Am. J. Pathol., 161: 781-786, 2002.
27. Klafter, R., and Arbiser, J. L. Regulation of angiogenesis and tumorigenesis by signal transduction cascades: lessons from benign and malignant endothelial tumors. J. Investig. Dermatol. Symp. Proc., 5: 79-82, 2000.
28. Gupta, S., Plattner, R., Der, C. J., and Stanbridge, E. J. Dissection of ras-dependent signaling pathways controlling aggressive tumor growth of human fibrosarcoma cells: evidence for a potential novel pathway. Mol. Cell. Biol., 20: 9294-9306, 2000.
29. Arbiser, J. L., Petros, J., Klafter, R., Govindajaran, B., McLaughlin, E. R., Brown, L. F., Cohen, C., Moses, M., Kilroy, S., Arnold, R. S., and Lambeth, J. D. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. USA, 99: 715-720, 2002.
30. Rak, J., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria-Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., and Kerbel, R. S. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res., 60: 490-498, 2000.
31. Ink4a and activation of MAP kinase. Mol. Med., 8: 1-8, 2002.
32. LaMontagne, K. R., Jr., Moses, M. A., Wiederschain, D., Mahajan, S., Holden, J., Ghazizadeh, H., Frank, D. A., and Arbiser, J. L. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am. J. Pathol., 157: 1937-1945, 2000.
33. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
34. Jacks, T., Remington, L., Williams. B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7. 1994.
35. Mandell, J. W., Hussaini, I. M., Zecevic, M., Weber, M. J., and VandenBerg, S. R. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol., 153: 1411-1423, 1998.
36. Gioeli, D., Mandell, J. W., Petroni, G. R., Frierson, H. F., Jr., and Weber, M. J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res., 59: 279-284, 1999.
37. Magi-Galluzzi, C., Mishra, R., Fiorentino, M., Montironi, R., Yao, H., Capodieci, P., Wishnow, K., Kaplan, I., Stork, P. J., and Loda, M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Investig., 76: 37-51, 1997.
38. Cohen, C., Zavala-Pompa, A., Sequeira, J. H., Shoji, M., Sexton, D. G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N., and Arbiser, J. L. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res., 8: 3728-3733. 2002.
39. Govindarajan, B., Bai, X., Cohen, C., Zhong, H., Kilroy, S., Moses, M., and Arbiser, J. L. Malignant transformation of melanocytes to melanoma by constitutive activation of MAP kinase kinase signaling. J. Biol. Chem., 278: 9790-9795, 2003.
40. Shepherd, C. W., Gomez, M. R., Lie, J. T., and Crowson, C. S. Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc., 66: 792-796, 1991.
41. Jin, F., Wienecke, R., Xiao, G. H., Maize, J. C., Jr., DeClue, J. E., and Yeung, R. S. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc. Natl. Acad. Sci. USA, 93: 9154-9159, 1996.
42. Kwiatkowski, D. J., Zhang, H., Bandura, J. L., Heiberger, K. M., Glogauer, M., el Hashemite, N., and Onda, H. A mouse model of TSC 1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet., 11: 525-534, 2002.
43. Kobayashi, T., Minowa, O., Sugitani, Y., Takai, S., Mitani, H., Kobayashi, E., Noda, T., and Hino, O. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc. Natl. Acad. Sci. USA, 98: 8762-8767, 2001.
44. Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O., and Noda, T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res., 59: 1206-1211, 1999.
45. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., and Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell, 10: 151-162, 2002.
46. Goncharova, E. A., Goncharov, D. A., Eszterhas, A., Hunter, D. S., Glassberg, M. K., Yeung, R. S., Walker, C. L., Noonan, D., Kwiatkowski, D. J., Chou, M. M., Panettieri, R. A., Jr., and Krymskaya, V. P. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the tsc2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem., 277: 30958-30967, 2002.
47. Nellist, M., Goedbloed, M. A., De Winter, C., Verhaaf, B., Jankie, A., Reuser, A. J., van den Ouweland, A. M., van der, S. P., and Halley, D. J. Identification and characterization of the interaction between tuberin and 14-3-3ζ. J. Biol. Chem., 2002.
48. Aicher, L. D., Campbell, J. S., and Yeung, R. S. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis. J. Biol. Chem., 276: 21017-21021, 2001.
49. Gao, X., and Pan, D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev., 15: 1383-1392, 2001.
50. Yeung, R. S., Xiao, G. H., Jin, F., Lee, W. C., Testa, J. R., and Knudson, A. G. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl. Acad. Sci. USA, 91: 11413-11416, 1994.
51. Hino, O., Kobayashi, E., Hirayama, Y., Kobayashi, T., Kubo, Y., Tsuchiya, H., Kikuchi, Y., and Mitani, H. Molecular genetic basis of renal carcinogenesis in the Eker rat model of tuberous sclerosis (Tsc2). Mol. Carcinog., 14: 23-27, 1995.
52. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., and Lydon, N. B. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 295: 139-145, 2000.
53. Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P., and Grant, S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with ST1571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res., 62: 188-199, 2002.
54. Burke, P., Schooler, K., and Wiley, H. S. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell, 12: 1897-1910, 2001.